BR112017020008A2 - peptídeos isolados e seus fragmentos a partir do fibrinogênio para uso como fármacos, particularmente em doenças inflamatórias da pele - Google Patents

peptídeos isolados e seus fragmentos a partir do fibrinogênio para uso como fármacos, particularmente em doenças inflamatórias da pele

Info

Publication number
BR112017020008A2
BR112017020008A2 BR112017020008A BR112017020008A BR112017020008A2 BR 112017020008 A2 BR112017020008 A2 BR 112017020008A2 BR 112017020008 A BR112017020008 A BR 112017020008A BR 112017020008 A BR112017020008 A BR 112017020008A BR 112017020008 A2 BR112017020008 A2 BR 112017020008A2
Authority
BR
Brazil
Prior art keywords
skin diseases
inflammatory skin
fragments
isolated peptides
fibrinogen
Prior art date
Application number
BR112017020008A
Other languages
English (en)
Other versions
BR112017020008A8 (pt
Inventor
Raingeaud Joël
Dupin Nicolas
Grange Philippe
Calvez Vincent
Original Assignee
Hopitaux Paris Assist Publique
Centre Nat Rech Scient
Roussy Inst Gustave
Inst Nat Sante Rech Med
Univ Paris Descartes
Univ Paris Sud
Univ Pierre Et Marie Curie Paris 6
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hopitaux Paris Assist Publique, Centre Nat Rech Scient, Roussy Inst Gustave, Inst Nat Sante Rech Med, Univ Paris Descartes, Univ Paris Sud, Univ Pierre Et Marie Curie Paris 6 filed Critical Hopitaux Paris Assist Publique
Publication of BR112017020008A2 publication Critical patent/BR112017020008A2/pt
Publication of BR112017020008A8 publication Critical patent/BR112017020008A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

a presente invenção se refere a peptídeos isolados obtidos a partir do fibrinogênio humano para o seu uso como fármaco, particularmente para a prevenção e/ou tratamento de doenças de pele inflamatórias, mais particularmente acne. a presente invenção também se refere a fragmentos desses polipeptídeos, moléculas de ácido nucléico codificando-os, vetores de expressão, células hospedeiras, uma composição farmacêutica e um produto de combinação contendo-os, e o seu uso para o tratamento e/ou prevenção de doenças de pele inflamatórias, particularmente acne.
BR112017020008A 2015-03-20 2016-03-21 Peptídeos isolados e seus fragmentos a partir do fibrinogênio para uso como fármacos, particularmente em doenças inflamatórias da pele BR112017020008A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15305414 2015-03-20
PCT/EP2016/056179 WO2016150926A1 (en) 2015-03-20 2016-03-21 Isolated peptides and fragments thereof from fibrinogen for use as drugs, particularly in skin inflammatory diseases

Publications (2)

Publication Number Publication Date
BR112017020008A2 true BR112017020008A2 (pt) 2018-06-19
BR112017020008A8 BR112017020008A8 (pt) 2023-05-02

Family

ID=52807757

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017020008A BR112017020008A8 (pt) 2015-03-20 2016-03-21 Peptídeos isolados e seus fragmentos a partir do fibrinogênio para uso como fármacos, particularmente em doenças inflamatórias da pele

Country Status (10)

Country Link
US (1) US10323078B2 (pt)
EP (1) EP3270950B1 (pt)
JP (1) JP6840086B2 (pt)
CN (1) CN107636011B (pt)
AU (1) AU2016236297B2 (pt)
BR (1) BR112017020008A8 (pt)
CA (1) CA2979812C (pt)
DK (1) DK3270950T3 (pt)
ES (1) ES2880795T3 (pt)
WO (1) WO2016150926A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117304303B (zh) * 2023-07-14 2024-07-05 杭州恩和生物科技有限公司 纤连蛋白截短片段、组合物及用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5433190A (en) * 1989-04-10 1990-11-16 Louisiana State University And Agricultural And Mechanical College Lytic peptides, use for growth, infection and cancer
US5639940A (en) * 1994-03-03 1997-06-17 Pharmaceutical Proteins Ltd. Production of fibrinogen in transgenic animals
US6783961B1 (en) * 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
AU2002316604A1 (en) * 2001-07-06 2003-01-21 Oregon Health And Science University Peptides which modulate blood coagulation and methods of use thereof
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20070172471A1 (en) * 2003-04-23 2007-07-26 Hansa Medical Ab Method for identifying an anti- streptococcal agent and its use for treating streptococcal infections
TW200732472A (en) * 2005-10-21 2007-09-01 Hoffmann La Roche Method for the recombinant expression of a polypeptide
US20130280820A1 (en) * 2005-12-16 2013-10-24 Schering Corporation Biomarkers for psoriasis
JP5547480B2 (ja) * 2006-08-04 2014-07-16 エスティービー リミテッド 創傷組織を治療するための固体包帯材の製造方法
WO2008116468A2 (en) * 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
CN101618211A (zh) * 2008-07-03 2010-01-06 珠海联邦制药股份有限公司 一种乙肝多肽疫苗及其应用
AU2009268052B2 (en) * 2008-07-09 2015-05-28 Mallinckrodt Pharma Ip Trading D.A.C. Recombinant fibrinogen
US20120052066A1 (en) * 2008-11-07 2012-03-01 Cesar Calderon Markers and methods for assessing and treating lupus patients susceptible to photoprovocation
EP4012714A1 (en) * 2010-03-23 2022-06-15 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
CA3067295C (en) * 2011-02-02 2022-06-21 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Anti-carbamylated protein antibodies and the risk for arthritis

Also Published As

Publication number Publication date
CN107636011A (zh) 2018-01-26
US20180105574A1 (en) 2018-04-19
EP3270950A1 (en) 2018-01-24
DK3270950T3 (da) 2021-06-07
AU2016236297A1 (en) 2017-09-28
JP6840086B2 (ja) 2021-03-10
BR112017020008A8 (pt) 2023-05-02
CA2979812C (en) 2023-08-29
CN107636011B (zh) 2021-07-02
CA2979812A1 (en) 2016-09-29
EP3270950B1 (en) 2021-04-21
AU2016236297B2 (en) 2020-07-23
US10323078B2 (en) 2019-06-18
JP2018512844A (ja) 2018-05-24
ES2880795T3 (es) 2021-11-25
WO2016150926A1 (en) 2016-09-29

Similar Documents

Publication Publication Date Title
CL2021002094A1 (es) Moléculas de anticuerpo para el tratamiento del cáncer. (divisional solicitud 201803153)
MX2019011215A (es) Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos.
BR112015011158A2 (pt) triazolopirazina
BR112016015818A2 (pt) Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1
EP4378962A3 (en) Anti-cancer fusion polypeptide
MX2017014716A (es) Polipeptido de fusion anti-cancer.
BR112017011923A2 (pt) bactéria modificada para tratar doenças associadas com hiperamonemia
BR112016016658A2 (pt) proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
BR212016030926U2 (pt) conjugados de alvo e partículas e formulações dos mesmos
CL2021000207A1 (es) Nuevas proteínas de fusión específicas para cd137 y pd-l1
BR112016022553A2 (pt) Compostos e métodos para entrega transmembrana de moléculas?
BR112015014372A8 (pt) inibidores de autotaxina, seus usos, e composição e combinação farmacêuticas".
BR112016002753A2 (pt) anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
BR112016027871A2 (pt) composição para melhorar a memória, a função de aprendizado e/ou função cognitiva
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
BR112016027024A2 (pt) polipeptídeos de ligação específica e seus usos
BR112014027981A2 (pt) compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
BR112012009432A2 (pt) anticorpo anti-hsv
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
BR112016024421A2 (pt) composição farmacêutica, cápsula e uso da composição farmacêutica
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
MY191980A (en) Formulations containing an extract of echinacea and linoleic acid derivatives
EA201790349A1 (ru) Производные 6-алкинил-пиридина в качестве миметиков белка smac
BR112017000898A2 (pt) oritavancina de alta pureza e método de produção da mesma

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B25A Requested transfer of rights approved

Owner name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) ; UNIVERSITE PARIS-SUD (FR) ; UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) ; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) ; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) ; INSTITUT GUSTAVE-ROUSSY (FR) ; UNIVERSITE DE PARIS (FR)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2715 DE 17-01-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B25D Requested change of name of applicant approved

Owner name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) ; UNIVERSITE PARIS-SUD (FR) ; UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) ; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) ; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) ; INSTITUT GUSTAVE-ROUSSY (FR) ; UNIVERSITE PARIS CITE (FR)